Centre Hospitalier de l'Université de Montréal (CHUM)
Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada10 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC | mCRPC | Active, not recruiting | Phase 3 | 2026-09-29 | NCT03395197 | |
| Viscoelasticity Imaging to Assess Liver Cancer | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Site, liver cancer, liver disorder, neoplasm | Recruiting | Not stated | 2026-09-17 | NCT04409340 | |
| A Multicenter Randomized Controlled Trial to Treat Acute T Cell Mediated Rejection in Kidney and Kidney-Pancreas Transplant Recipients | Rejection; Transplant, Kidney; Rejection; Transplant, Pancreas | Recruiting | Phase 3 | 2026-08-31 | NCT06474273 | |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm, susceptibility to familial cutaneous melanoma | Recruiting | Phase 3 | 2026-08-18 | NCT06743126 | |
| Early Detection of Liver Cancer by QUS | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenocarcinoma, carcinoma, disease, epithelial neoplasm, hepatocellular carcinoma, liver cancer, liver disorder, neoplasm | Recruiting | Not stated | 2026-03-20 | NCT06345508 | |
| Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder | Chemically-Induced Disorders, psychiatric disorder, substance abuse, substance-related disorder | Recruiting | Phase 2 | 2026-02-23 | NCT06788587 | |
| Effectiveness of an Enhanced Recovery After Surgery Protocol in Patients Undergoing On-pump Cardiac Surgery | Disorder; Heart, Functional, Postoperative, Cardiac Surgery | Not yet recruiting | Not stated | 2025-09-18 | NCT05225272 | |
| Evaluation of the Optilume BPH Catheter System and the Rezum Water Vapor Therapy in Treating Benign Prostatic Hyperplasia | Genital Diseases, Male Urogenital Diseases, Urogenital Diseases, benign prostatic hyperplasia, male reproductive system disorder, prostate disorder | Recruiting | Not applicable | 2025-07-17 | NCT06769997 | |
| TH1902 in Patients With Advanced Solid Tumors | Adnexal Diseases, Carcinoma, Ovarian Epithelial, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cutaneous melanoma, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, hormone receptor-positive breast cancer, lung disorder, lung neoplasm, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, ovarian cancer, ovarian disorder, primitive neuroectodermal tumor, prostate cancer, prostate disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, small cell lung carcinoma, thyroid gland disorder, thyroid tumor, triple-negative breast carcinoma, uterine disorder | Active, not recruiting | Phase 1 | 2025-04-15 | NCT04706962 | |
| Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Liver Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, hepatocellular carcinoma, liver disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, respiratory system disorder, respiratory tract neoplasm, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Phase 2 | 2022-03-31 | NCT03836352 |